Plenary Speakers:
	Christopher B. Begley, MBA, Chief Executive Officer, Hospira, Inc.		Jeremy Levin, D. Phil, MB. Bchir, Global Head, Business Development and Strategic Alliances, Novartis (provisionally confirmed)
	Mikael Dolsten, M.D., Ph.D., Executive Vice President, Pharma Research, Boehringer Ingelheim Pharmaceuticals, Inc.		Wade Speir, Managing Consultant, PA Consulting Group
	Rainer Fuchs, Ph.D., Co-Head Discovery Research and Vice President, Research Informatics, BiogenIdec, Inc.		Kathleen Metters, Ph.D., Senior Vice President and Head, Worldwide Basic Research, Merck & Co, Inc.
	Joanne M. Killinger, Ph.D., D.A.B.T., Senior Vice President, Drug Safety and Metabolism, Wyeth Research		Adrian Otte, M.B., BCh., F.F.P.M., Senior Vice President, Worldwide Development Operations, Pfizer Inc.
	Lawrence J. Lesko, Ph.D., F.C.P., Director, Office of Clinical Pharmacology, Food and Drug Administration

Hear Pharmaceutical and Biotech Leaders Present on the Following Topics:

• Translational Medicine’s Impact or Non-Impact on R&D Productivity in the Near Term

• The Globalization of Drug Development with Emphasis on China and India

• How Can Changes in the R&D Business Model Enable Better Risk Management

• How Should We Approach Our Portfolio Strategy Moving into the Future?

• Re-Engineering Drug Safety Risk Management Models

Networking Features Include:

• Executive Roundtable Discussions

• Executive Dinner Roundtables

• Three Concurrent, Interactive Breakout Sessions

• Two Concurrent Biotech and Pharmaceutical Breakout Sessions

---

Leadership Presenters

Christopher B. Begley MBA, Chief Executive Officer, Hospira Inc. David Brewster, Ph.D., F. Hoffman La-Roche, Inc. Claudio Carini, M.D., Ph.D., FRCPath, MDS Pharma Wayne Carter, DVM, Ph.D., Pfizer Inc. Parimal R. Desai, Ph.D., Wyeth Research Mikael Dolsten, M.D., Ph.D., Boehringer Ingelheim Pharmaceuticals, Inc. Paul Fielder, Ph.D., Genentech, Inc. Rainer Fuchs, Ph.D., Biogen Idec,Inc. Mark Gurney, deCODE genetics, Inc. Sanjay Jariwala, Ph.D., Aspreva Pharmaceuticals Corporation Richard Heaslip, Ph.D., Wyeth Marc L. Hoffman, M.D., Baxter Healthcare Corporation Mark Horn, Wyeth Joanne Killinger, Ph.D., D.A.B.T, Wyeth Research

Michael Leonetti, Boehringer Ingelheim Pharmaceuticals, Inc. Lawrence J. Lesko, Ph.D., F.C.P., Food and Drug Administration Jeremy Levin, D. Phil, MB. Bchir, Novartis (provisionally confirmed) Wade Speir, Managing Consultant, PA Consulting Group Julio Camps, M.D., Director, Latin America Development, Latin, India and Asia Operations, Amgen, Inc. Charles Morris, M.D., AstraZeneca Michael Needle, M.D., Celgene Corporation Timothy Noffke, PMP, Integrated Project Management Company Adrian Otte MB., BCh., F.F.P.M., Pfizer Inc. Richard Owen, PA Consulting Kristian Saksida, Solvay Pharmaceuticals Ingelheim Pharmaceuticals, Inc. Kohkan Shamsi, M.D., Ph.D., Berlex, Inc. Jeffrey L. Winkelhake, Ph.D., Sinobiopharmaceuticals, Ltd. Hans Winkler, Ph.D., Johnson & Johnson Pharmaceutical R&D

---

EARN up to 2 PDUs! PMPs certified by the Project Management Institute (PMI) are eligible to receive credits for The Pharmaceutical Biotech Leaders Summit Conference.  Attendees will need to retain the necessary supportive documentation for this type of activity as specified in the PMP Handbook and submit their credit application directly to PMI. PMPs may submit PDUs up to twelve months after the expiration date of the cycle in which the activities were completed. This applies to credits needed for the minimum requirements of the cycle and any transferable credits completed during cycle. Note: All of the required PDUs must be completed and reported no later than the expiration date of the PMP s cycle to avoid suspension. Cambridge Healthtech Institute (CHI) is a Project Management Institute (PMI®) Registered Education Provider (R.E.P.). CHI is committed to enhancing the ongoing professional development of PMI Members. PMI-certified Project Management Professionals (PMP®) and other project management stakeholders through appropriate project management learning activities and products. As a PMI R.E.P., CHI has agreed to abide by PMI-established operational and educational criteria, and is subject to random audits for quality assurance purposes. For more information contact Lisa Scimemi at lscimemi@healthtech.com

For sponsorship information, please contact:
Laura Ames, Cambridge Healthtech Institute
Phone: 781-972-5479 Email: lames@healthech.com